Daiichi Sankyo
211 Mt. Airy Road
Basking Ridge
New Jersey
07920
United States
Tel: (908) 992-6400
Website: http://www.daiichisankyo.com/
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.
With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.
For more information, please visit: www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.
STOCK EXCHANGE: Tokyo Stock Exchange
STOCK SYMBOL: 4568
521 articles about Daiichi Sankyo
-
Daiichi Sankyo Co Ltd. Now Opens Office in Turkey
8/6/2008
-
Biota Holdings Limited Release: LANI Phase II Completed -- Phase III Scheduled
7/31/2008
-
Daiichi Sankyo Co Ltd. and Ranbaxy Laboratories Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
7/17/2008
-
Seattle Genetics, Inc. Announces Antibody-Drug Conjugate Collaboration with Daiichi Sankyo Co Ltd.; Seattle Genetics Will Receive Upfront Payment of $4M
7/8/2008
-
Small is Beautiful -- BioPharm Executive
6/25/2008
-
FDA Extends Review Period for Daiichi Sankyo Co Ltd., Eli Lilly and Company Investigative Antiplatelet Drug, Prasugrel
6/24/2008
-
Ranbaxy Laboratories to Bring in Daiichi Sankyo Co Ltd. as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
6/11/2008
-
KineMed, Inc. and Daiichi Sankyo Co Ltd. Release: New Discovery of Key Difference in Bile Acid Metabolism in Patients With Type 2 Diabetes May Suggest Underlying Disorder
6/9/2008
-
Daiichi Sankyo Co Ltd. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent
5/30/2008
-
Daiichi Sankyo Co Ltd. to Buy U3 Pharma for US $234M (150M Euros)
5/21/2008
-
Daiichi Sankyo Co Ltd. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
5/19/2008
-
Daiichi Sankyo Co Ltd. Release: Data From Pooled Analyses Demonstrates Welchol, Combined With Metformin -- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults With Type 2 Diabetes
5/16/2008
-
Daiichi Sankyo Co Ltd. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
5/16/2008
-
Daiichi Sankyo Co Ltd. Release: AZOR(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
5/15/2008
-
Daiichi Sankyo Co Ltd. Release: New Data Shows 45 Percent of Patients With Stage 1 Hypertension Reached Normotension With BENICAR(R) and BENICAR HCT(R)
5/14/2008
-
Daiichi Sankyo Co Ltd. New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) Data Presented at the American Society of Hypertension's Twenty-Third Annual Scientific Meeting
5/14/2008
-
Forest Laboratories, Inc. and Daiichi Sankyo Co Ltd. Announce the Termination of the AZOR Co-Promotion Agreement
5/12/2008
-
Daiichi Sankyo Co Ltd. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists 'Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus'
4/15/2008
-
Daiichi Sankyo Co Ltd. Says U.S. FDA Rejects Anaemia Drug
3/12/2008
-
Daiichi Sankyo, Inc. Grants Priority Review for Daiichi Pharmaceutical Co., Ltd., Daiichi Pharmaceutical Co., Ltd. Drug, Prasugrel Investigational Antiplatelet Agent
2/22/2008